Lapix Therapeutics Inc.
Cambridge, MA · Founded 2019 · CIK 0001947620 · Biotech · Private
Orally bioavailable small molecule therapeutics for immune system restoration
lapix.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $12M
- 4 Form D · Aug 2025
- 14 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 23
- 3 granted · 20 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,247,500 | |
| Private capital raised | Form D · SEC | $5,947,478 | |
| Private capital raised | Form D · SEC | $2,219,990 | |
| Private capital raised | Form D · SEC | $2,200,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1461 | Cage Bio, Inc. | — | $19M |
| 1462 | PridCor Therapeutics, LLC | — | $6.0M |
| 1463 | BLUESTEM BIOSCIENCES INC | — | $5.0M |
| 1464 | Lapix Therapeutics Inc. | — | $12M |
| 1465 | ANDSON BIOTECH INC. | — | $8.3M |
| 1466 | GC Therapeutics | — | — |
| 1467 | Endogenex, Inc. | — | $122M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Anas FathallahDirector · Executive Officer
- Anthony GibneyDirector
- Francisco LeonDirector
- Henry McKinnellDirector
- Jason NorrisDirector · Executive Officer
Patents
- Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disordersapplication
- Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disordersgranted
- Tartaric Acid Analogs and Uses Thereofapplication
- Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disordersapplication
- Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disordersgranted
- Compositions and Methods For Reducing Immune Intoleranceapplication
- Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disordersgranted
- Immune Cell-engrafted Non-human Animals And Non-human Animal Modelsapplication
- XenoImmune Animal and XenoImmune Animal Modelapplication
- Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disordersapplication
- XenoImmune Animal and XenoImmune Animal Modelapplication
- Compositions And Methods For Reducing Immune Intolerance And Treating Autoimmune Disordersapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.